ELIMED/ELIMAIA: The First Users Beamline Dedicated to Irradiation Studies with Laser-driven Ion Beams
Author | : G. P. Cirrone |
Publisher | : |
Total Pages | : |
Release | : 2017 |
ISBN-10 | : OCLC:1163840649 |
ISBN-13 | : |
Rating | : 4/5 (49 Downloads) |
Book excerpt: ELIMED/ELIMAIA: the first Users beamline dedicated to irradiation studies with laser-driven ion beamsGAP Cirrone(1,2,*), G Cuttone (1), G Korn(2), G Larosa(1), PA Lojacono (1), G Petringa(1), A Russo(1), F Schillaci(2), V Scuderi(2) and D Margarone(1)(1) INFN-LNS (Istituto Nazionale di Fisica Nucleare- Laboratori Nazionali del Sud, Catania, Italy)(2) ELI-Beamline Project, (Inst. Physics, ASCR, PALS Center, Prague, Czech Republic)(3) Queens University, Belfast, UK(*) Corresponding author [email protected] main direction proposed by the community in the field of laser-driven ion acceleration is to improve particle beam features in order to demonstrate reliable approaches to be used for multidisciplinary applications.The mission of the laser-driven ion target area at ELI-Beamlines (Extreme Light Infrastructure) in Czech Republic, called ELI Multidisciplinary Applications of laser-Ion Acceleration (ELIMAIA), is to provide stable, fully characterized and tuneable beams of particles accelerated by Petawatt-class lasers and to offer them to the user community for multidisciplinary applications. The focusing, selecting, measuring and irradiating parts of ELIMAIA, constitutes the so-called ELIMED (ELI MEDical and multidisciplinary applications) portion. At ELIMED, very high-dose-rate (not less than 10^5 Gy/min) controlled proton and ion beams, with energy ranging from 5 to 250 MeV, will be transported up to the in-air section where absolute dosimetry will be carried out. A transmission, dual-gap air ionisation chamber will provide the on-line measure of the dose at the irradiation point. The maximum expected error in the final dose released to the sample is expected to be within 5%. ELIMED first irradiation is scheduled for 2020 when the first radiobiological campaign for in-vitro cells irradiation with controlled fast beams is expected. In this work, the status of the ELIMED/ELIMAIA beamline will be reported along with a complete description of the main dosimetric systems and of the first preliminary calibrations. The expected final beam characteristics, in terms of dose per pulse, dose-rate, beam spot size, directly derived by Monte Carlo simulations, will be reported, as well.